N/A N=53 Web-based Addiction Treatment: Cultural Adaptation With American Indians
Substance Use Disorders
Primary: Consecutive Weeks of Drug/Alcohol Abstinence — 2.0; 2.0 Weeks — p=0.437
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Phase 3 N=100 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Atrial Fibrillation · Stroke · Bleeding
Primary: Postoperative Length of Stay — 8; 7 days
Phase 2 N=51 Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Cicatricial Alopecia
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants
N/A N=148 Effect of Personalized Pain Coaches After Orthopaedic Surgery for Patients With Sports Medicine Injuries
Sports Medicine Injuries
Primary: Pain Numerical Rating Scale (NRS) — 3.24; 3.04; 2.98; 3.02 score on a scale
Phase 3 N=559 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Overall Survival — 9.4; 10.5 months — p=0.0399
Phase 3 N=106 Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
Surgery · Analgesia
Primary: Analgesia Assessed by the Area Under the Curve of Visual Analog Scale Pain Intensity Scores — 87.1; 92.8 VAS score x Hours
Phase 3 N=15 A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
Primary Immunodeficiency Diseases (PID)
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100 percentage of participants
Phase 3 N=2,620 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
Respiratory Syncytial Virus Infections
Primary: RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination — 5676.7; 6329.5 Titer
Phase 4 N=54 A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Uncontrolled Gout · Chronic Gout
Primary: Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 68.0; 73.1 percentage of participants
Phase 3 N=511 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Safety run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment. — 0 Participants
N/A N=219 Antibiotic Prophylaxis in Percutaneous Nephrostomy Placements and Replacements for Malignant Urinary Tract Obstruction
Ureteral Obstruction · Neoplasms · Acute Kidney Injury
Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548
Phase 3 N=370 Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 27.2; 26.0 score…
N/A N=6 Development and Validation of Virtual Laparoscopic Hiatal Hernia Simulator
Predictive Validity of VLaHHS
Primary: Skill Level in Participants as Assessed by Completion Time — 492.7; 1086.07 Seconds